Drug Profile
Ichorcumab - Johnson & Johnson Innovative Medicine
Alternative Names: JNJ 9375; JNJ-375; JNJ-64179375Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cambridge University Hospitals; University of Cambridge
- Developer Johnson & Johnson Innovative Medicine
- Class Anticoagulants; Antithrombotics; Monoclonal antibodies
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 01 Oct 2023 Janssen Pharmaceuticals is now called Johnson & Johnson Innovative Medicine (Janssen Pharmaceuticals website, October 2023)
- 07 Dec 2022 No development reported - Phase-II for Thrombosis (Prevention) in Greece, Portugal, USA, Argentina, Brazil, Bulgaria, Canada, Italy, Japan, Latvia, Lithuania, Malaysia, Poland, Russia, Turkey, Ukraine, Sweden, Spain, Belgium (IV)
- 28 Oct 2020 No recent reports of development identified for phase-I development in Thrombosis(In volunteers) in United Kingdom (IV)